Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB15010 in advanced solid tumors
NCT06819215Phase 2Recruiting
- Sponsor
- Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vb15010 in solid tumor (advanced stage) and prostate cancer (PCa), sponsored by Shenzhen Yangli Pharmaceutical Technology Co. Ltd. Primary endpoints: Number of subjects with adverse events/serious adverse events and Number of subjects with dose-limiting toxicity. Started Oct 2024; status: recruiting.
02
Drugs
vb15010
03
Conditions
solid tumor (advanced stage)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06819215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819215.